Helus Pharma (HELP)
Market Price (9/9/2026): $13.71 | Market Cap: $717.3 MilSector: Health Care | Industry: Biotechnology
Helus Pharma (HELP)
Market Price (9/9/2026): $13.71Market Cap: $717.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns3Y Excs Rtn is -9.9% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -167 Mil Stock price has recently run up significantly6M Rtn6 month market price return is 116% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% Key risksHELP key risks include [1] the successful clinical development and manufacturing scale-up of its lead drug candidates HLP003 and HLP004, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -9.9% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -167 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 116% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% |
| Key risksHELP key risks include [1] the successful clinical development and manufacturing scale-up of its lead drug candidates HLP003 and HLP004, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/4/2026
Helus Pharma (HELP) stock has gained about 170% since 5/31/2026 because of the following key factors:
1. Accelerated clinical progress for HLP003, a Breakthrough Therapy-designated drug for Major Depressive Disorder (MDD). Helus Pharma completed enrollment in its Phase 3 APPROACH pivotal study for HLP003 ahead of schedule by July 21, 2026, after having surpassed 86% enrollment by June 24, 2026. HLP003 has received Breakthrough Therapy Designation from the FDA, and topline data from the APPROACH study are anticipated in Q4 2026. Earlier Phase 2 data demonstrated a significant ~23-point reduction in the MADRS score at 12 months, with response and remission rates of 100% and 71% respectively (or 100% remission using a MADRS ≤12 threshold). This rapid advancement towards a key data readout for a potentially transformative treatment in a large market has been a significant driver for the stock's performance.
2. Positive Phase 2 results for HLP004 in Generalized Anxiety Disorder (GAD). The company reported positive topline results from its Phase 2 signal detection study for HLP004, showing an approximately 10-point improvement from baseline in HAM-A on top of standard of care at six weeks. Following these promising results, Helus Pharma announced its intention to complete the design of the next HLP004 study by the end of fiscal Q3 2026.
Show more
Helus Pharma (HELP) stock has gained about 170% since 5/31/2026 because of the following key factors:
1. Accelerated clinical progress for HLP003, a Breakthrough Therapy-designated drug for Major Depressive Disorder (MDD). Helus Pharma completed enrollment in its Phase 3 APPROACH pivotal study for HLP003 ahead of schedule by July 21, 2026, after having surpassed 86% enrollment by June 24, 2026. HLP003 has received Breakthrough Therapy Designation from the FDA, and topline data from the APPROACH study are anticipated in Q4 2026. Earlier Phase 2 data demonstrated a significant ~23-point reduction in the MADRS score at 12 months, with response and remission rates of 100% and 71% respectively (or 100% remission using a MADRS ≤12 threshold). This rapid advancement towards a key data readout for a potentially transformative treatment in a large market has been a significant driver for the stock's performance.
2. Positive Phase 2 results for HLP004 in Generalized Anxiety Disorder (GAD). The company reported positive topline results from its Phase 2 signal detection study for HLP004, showing an approximately 10-point improvement from baseline in HAM-A on top of standard of care at six weeks. Following these promising results, Helus Pharma announced its intention to complete the design of the next HLP004 study by the end of fiscal Q3 2026.
Show more
Updated on 9/4/2026
Helus Pharma (HELP) stock has gained about 170% since 5/31/2026 because of the following key factors:
1. Accelerated clinical progress for HLP003, a Breakthrough Therapy-designated drug for Major Depressive Disorder (MDD). Helus Pharma completed enrollment in its Phase 3 APPROACH pivotal study for HLP003 ahead of schedule by July 21, 2026, after having surpassed 86% enrollment by June 24, 2026. HLP003 has received Breakthrough Therapy Designation from the FDA, and topline data from the APPROACH study are anticipated in Q4 2026. Earlier Phase 2 data demonstrated a significant ~23-point reduction in the MADRS score at 12 months, with response and remission rates of 100% and 71% respectively (or 100% remission using a MADRS ≤12 threshold). This rapid advancement towards a key data readout for a potentially transformative treatment in a large market has been a significant driver for the stock's performance.
2. Positive Phase 2 results for HLP004 in Generalized Anxiety Disorder (GAD). The company reported positive topline results from its Phase 2 signal detection study for HLP004, showing an approximately 10-point improvement from baseline in HAM-A on top of standard of care at six weeks. Following these promising results, Helus Pharma announced its intention to complete the design of the next HLP004 study by the end of fiscal Q3 2026.
3. Successful completion of a $50 million underwritten public offering. On June 25, 2026, Helus Pharma closed an underwritten offering of 10,309,280 common shares at an offering price of $4.85 per share, raising aggregate gross proceeds of $50 million. The company stated that the proceeds are intended to fund the progression of its HLP003, HLP004, and HLP005 programs, as well as for working capital and general corporate purposes. This capital raise strengthened the balance sheet, with cash totaling $166.4 million as of June 30, 2026 (the end of fiscal Q1 2027), and signaled strong institutional investor confidence in its clinical strategy.
4. Strategic appointment of a new Chief Executive Officer with significant industry experience. Helus Pharma appointed Michael Halstead as its Chief Executive Officer on August 3, 2026. Halstead brings 25 years of industry experience, including leading Intra-Cellular Therapies through the development and commercialization of CAPLYTA and its subsequent $14.6 billion sale to Johnson & Johnson. This appointment is perceived as a strong signal for the company's focus on late-stage development and commercialization, given Halstead's proven track record in the pharmaceutical industry.
Show less
Helus Pharma (HELP) stock has gained about 170% since 5/31/2026 because of the following key factors:
1. Accelerated clinical progress for HLP003, a Breakthrough Therapy-designated drug for Major Depressive Disorder (MDD). Helus Pharma completed enrollment in its Phase 3 APPROACH pivotal study for HLP003 ahead of schedule by July 21, 2026, after having surpassed 86% enrollment by June 24, 2026. HLP003 has received Breakthrough Therapy Designation from the FDA, and topline data from the APPROACH study are anticipated in Q4 2026. Earlier Phase 2 data demonstrated a significant ~23-point reduction in the MADRS score at 12 months, with response and remission rates of 100% and 71% respectively (or 100% remission using a MADRS ≤12 threshold). This rapid advancement towards a key data readout for a potentially transformative treatment in a large market has been a significant driver for the stock's performance.
2. Positive Phase 2 results for HLP004 in Generalized Anxiety Disorder (GAD). The company reported positive topline results from its Phase 2 signal detection study for HLP004, showing an approximately 10-point improvement from baseline in HAM-A on top of standard of care at six weeks. Following these promising results, Helus Pharma announced its intention to complete the design of the next HLP004 study by the end of fiscal Q3 2026.
3. Successful completion of a $50 million underwritten public offering. On June 25, 2026, Helus Pharma closed an underwritten offering of 10,309,280 common shares at an offering price of $4.85 per share, raising aggregate gross proceeds of $50 million. The company stated that the proceeds are intended to fund the progression of its HLP003, HLP004, and HLP005 programs, as well as for working capital and general corporate purposes. This capital raise strengthened the balance sheet, with cash totaling $166.4 million as of June 30, 2026 (the end of fiscal Q1 2027), and signaled strong institutional investor confidence in its clinical strategy.
4. Strategic appointment of a new Chief Executive Officer with significant industry experience. Helus Pharma appointed Michael Halstead as its Chief Executive Officer on August 3, 2026. Halstead brings 25 years of industry experience, including leading Intra-Cellular Therapies through the development and commercialization of CAPLYTA and its subsequent $14.6 billion sale to Johnson & Johnson. This appointment is perceived as a strong signal for the company's focus on late-stage development and commercialization, given Halstead's proven track record in the pharmaceutical industry.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 172.3% change in HELP stock from 5/31/2026 to 9/8/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312026 | 9082026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.55 | 12.39 | 172.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 43 | 52 | -18.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2026 to 9/8/2026| Return | Correlation | |
|---|---|---|
| HELP | 172.3% | |
| Market (SPY) | 1.3% | 18.7% |
| Sector (XLV) | 11.8% | 11.1% |
Fundamental Drivers
The 68.6% change in HELP stock from 2/28/2026 to 9/8/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 9082026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.35 | 12.39 | 68.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 43 | 52 | -18.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 9/8/2026| Return | Correlation | |
|---|---|---|
| HELP | 68.6% | |
| Market (SPY) | 12.0% | 31.8% |
| Sector (XLV) | 4.8% | 27.2% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 9/8/2026| Return | Correlation | |
|---|---|---|
| HELP | ||
| Market (SPY) | 19.8% | 33.4% |
| Sector (XLV) | 23.2% | 21.8% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/8/2026| Return | Correlation | |
|---|---|---|
| HELP | ||
| Market (SPY) | 76.1% | 33.4% |
| Sector (XLV) | 31.3% | 21.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HELP Return | - | - | - | - | - | 58% | 58% |
| Peers Return | -54% | 104% | 3% | 6% | 116% | 13% | 154% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| HELP Win Rate | - | - | - | - | - | 67% | |
| Peers Win Rate | 50% | 67% | 50% | 50% | 58% | 67% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| HELP Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -76% | -53% | -36% | -33% | -31% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AXSM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/8/2026 (YTD)
How Low Can It Go
HELP has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
HELP has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Helus Pharma (HELP)
```html
Helus Pharma, trading under the symbol HELP, is a biopharmaceutical company dedicated to developing psychedelic-based therapeutics. The company focuses on leveraging novel compounds to address significant unmet needs in mental health and neurological conditions, positioning itself within the innovative landscape of psychedelic medicine.
The company's development pipeline features several key drug candidates. CYB003 is a deuterated psilocybin analog being developed for the treatment of major depressive and alcohol use disorders. Another prominent candidate, CYB004, is a deuterated dimethyltryptamine aimed at treating anxiety disorders. Additionally, Helus Pharma is exploring CYB005, a discovery-phase phenethylamine derivative, for its potential applications in neuroinflammation and various psychiatric conditions.
Beyond its pharmaceutical compounds, Helus Pharma also offers EMBARK, a proprietary psychedelic-assisted psychotherapy. The company primarily serves the healthcare market, with a focus on patients suffering from conditions such as depression, anxiety, alcohol use disorder, and other complex psychiatric and neuroinflammatory disorders. Its market encompasses the broader biopharmaceutical sector specializing in advanced mental health treatments.
```AI Analysis | Feedback
- Moderna for psychedelic medicine.
- A specialized Eli Lilly for psychedelic mental health treatments.
- An early Amgen, but for psychedelic therapeutics.
AI Analysis | Feedback
- CYB003: A deuterated psilocybin analog to treat major depressive and alcohol use disorders.
- CYB004: A deuterated dimethyltryptamine for treating anxiety disorders.
- CYB005: A discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions.
- EMBARK: A proprietary psychedelic-assisted psychotherapy program.
AI Analysis | Feedback
Note: The company described in the background is Cybin Inc. (symbol: CYBN), a biopharmaceutical company developing psychedelic-based therapeutics. The request specified "Helus Pharma" (symbol: HELP). This response is based on the company description provided for Cybin Inc., assuming it is the intended subject.
As Cybin Inc. is a biopharmaceutical company with its product pipeline (CYB003, CYB004, CYB005, and EMBARK) currently in clinical development stages, it does not yet have major commercial customers in the traditional sense of selling approved products. Upon potential market approval and commercialization, its major customers would primarily be other companies and institutions within the healthcare sector. These would include:
- Hospitals and Integrated Healthcare Networks: These institutions would purchase and administer Cybin's approved therapeutics and offer psychedelic-assisted psychotherapy for conditions such as major depressive disorder, alcohol use disorder, and anxiety disorders to their patients.
- Specialized Psychiatric and Addiction Treatment Centers: Private and public clinics focused on mental health and substance abuse treatment would be key adopters of Cybin's innovative therapies, integrating them into their treatment protocols.
- Pharmaceutical Distributors and Wholesalers: These companies would serve as intermediaries, purchasing the therapeutics from Cybin Inc. and managing their distribution to various healthcare providers and institutions.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
The key risks to Helus Pharma (trading under the symbol HELP), which is Cybin Inc. doing business as Helus Pharma, are primarily associated with the biopharmaceutical nature of its psychedelic-based therapeutics development.
- Clinical Development and Regulatory Approval Risk: Helus Pharma's success is highly dependent on the successful completion of clinical trials for its pipeline candidates, including CYB003 for major depressive and alcohol use disorders, CYB004 for anxiety disorders, and CYB005 for neuroinflammation and psychiatric conditions. The failure of any of these trials, or significant delays in their progress, could severely impact the company's financial health and future prospects. Furthermore, obtaining regulatory approvals for psychedelic-based therapeutics presents unique challenges due to the historical context and stringent regulatory scrutiny associated with these compounds.
- Intellectual Property Protection: As a biopharmaceutical company developing novel compounds like deuterated psilocybin and dimethyltryptamine analogs, Helus Pharma's intellectual property (IP) is critical to its business. The ability to secure, maintain, and defend patents for its drug candidates and therapeutic approaches is essential for market exclusivity and competitive advantage. Challenges to its existing patents, or the inability to obtain new patent protection, could allow competitors to develop similar products, eroding Helus Pharma's market share and profitability.
- Market Acceptance and Commercialization Challenges: Even upon successful regulatory approval, Helus Pharma faces risks related to the broad market acceptance and commercialization of its psychedelic-based therapeutics and associated psychotherapy programs like EMBARK. Overcoming the societal stigma historically associated with psychedelics, securing favorable reimbursement policies from payers, and gaining widespread adoption by healthcare providers and patients will be crucial for commercial success. Competition from existing and emerging treatments for mental health and alcohol use disorders could also limit its market penetration.
AI Analysis | Feedback
null
AI Analysis | Feedback
Helus Pharma (trading under symbol HELP), also known as Cybin Inc., is a biopharmaceutical company focused on developing psychedelic-based therapeutics for various mental health conditions. Below are the estimated addressable market sizes for their main product areas:
-
CYB003 (Deuterated psilocybin analog for Major Depressive Disorder and Alcohol Use Disorders):
- For Major Depressive Disorder, the global market size was estimated at approximately USD 6.84 billion in 2024 and is projected to reach USD 14.57 billion by 2033.
- For Alcohol Use Disorders, the global market was valued at USD 1.28 billion in 2024 and is expected to grow to USD 1.88 billion by 2030.
-
CYB004 (Deuterated dimethyltryptamine for Anxiety Disorders):
- The global anxiety disorder treatment market was estimated at USD 12.89 billion in 2024 and is projected to reach USD 17.57 billion by 2032.
-
CYB005 (Discovery-phase phenethylamine derivative for Neuroinflammation and Psychiatric Conditions):
- For Neuroinflammation, the global Neuroregeneration Therapy Market was estimated at USD 15.24 billion in 2025 and is projected to reach USD 41.98 billion by 2033. Additionally, the global anti-inflammatory therapeutics market size was calculated at USD 110.17 billion in 2025, projected to reach around USD 165.92 billion by 2035.
- For Psychiatric Conditions (broadly), the global mental health market size was approximately USD 490.91 billion in 2025 and is expected to reach around USD 682.51 billion by 2035. The global central nervous system (CNS) therapeutics market, which includes psychiatric disorders, was estimated at USD 138.59 billion in 2025 and is projected to reach USD 273.32 billion by 2033.
AI Analysis | Feedback
Helus Pharma, operating under the symbol HELP and formerly known as Cybin Inc., is a clinical-stage biopharmaceutical company with its financial model currently built entirely on the future commercialization of its drug candidates. The company is focused on developing psychedelic-based therapeutics for mental health conditions. Over the next 2-3 years, its expected drivers of future revenue growth are centered on the successful advancement and potential commercialization of its pipeline assets:
* Advancement and Commercialization of HLP003 (formerly CYB003) for Major Depressive Disorder (MDD): HLP003, a proprietary deuterated psilocybin analog, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Successful completion of Phase 3 trials and subsequent regulatory approval and market launch would be a primary driver of revenue.
* Advancement and Commercialization of HLP004 (formerly CYB004) for Generalized Anxiety Disorder (GAD): HLP004, a proprietary deuterated DMT molecule, is in Phase 2 clinical trials for treating generalized anxiety disorders. Positive clinical trial results, progression through later development stages, and eventual commercialization would contribute significantly to future revenue streams.
* Expansion and Monetization of the Intellectual Property Portfolio: Helus Pharma possesses an extensive intellectual property portfolio, including over 100 granted patents and more than 250 pending applications that provide protection for its lead programs, HLP003 and HLP004, until at least 2041. This robust IP strategy offers a competitive advantage and could be leveraged through licensing agreements or strategic partnerships to generate revenue.
* Strategic Collaborations and Partnerships: The company has already established a strategic partnership with Segal Trials to support its pivotal Phase 3 program for HLP003. Future collaborations with larger pharmaceutical companies or other industry players could provide crucial funding, accelerate development timelines, and facilitate broader market access for its therapeutic candidates, thereby indirectly driving revenue growth.
* Development and Future Launch of Additional Pipeline Candidates: Beyond its lead programs, Helus Pharma also has a research pipeline of investigational psychedelic-based compounds, including SPL028, SPL026, and CYB005, a phenethylamine derivative. Successful progression and eventual commercialization of these earlier-stage candidates could diversify the company's product offerings and create additional revenue streams in the medium to long term.
AI Analysis | Feedback
null
Peer Outperformance in Biotechnology
nullShare of Biotechnology constituents that HELP has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
—
insufficient peer history
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is HELP's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.8% | 84.9% | 84.9% | CAH 403% · MCK 345% · COR 177% |
| Managed Health Care | 8 | 32.5% | -3.8% | 4.9% | OSCR 88% · HQY 42% · ELV 16% |
| Health Care Services | 20 | 18.6% | 52.5% | -0.2% | HIMS 211% · RDNT 148% · DGX 65% |
| Health Care Facilities | 24 | -1.4% | 2.5% | -16.6% | NHC 258% · THC 249% · ENSG 115% |
| Health Care Equipment | 50 | -5.1% | -1.7% | -26.0% | POCI 10862% · UFPT 333% · GKOS 236% |
| Pharmaceuticals | 62 | -3.4% | 4.3% | -36.8% | LQDA 2343% · INDV 1115% · ETON 1064% |
| Health Care Supplies | 12 | 25.0% | -11.8% | -37.2% | LNTH 284% · HAE 57% · MMSI 22% |
| Life Sciences Tools & Services | 109 | 1.5% | -24.7% | -70.8% | SNWV 1598% · MEDP 206% · AXGN 171% |
| Health Care Technology | 20 | -23.6% | -53.3% | -78.1% | SPOK 73% · HSTM -3% · VEEV -13% |
| Biotechnology ← | 363 | 3.8% | -24.6% | -79.5% | DNTH 1619% · CELZ 1443% · ELVN 1243% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 110.10 |
| Mkt Cap | 5.7 |
| Rev LTM | 388 |
| Op Inc LTM | -175 |
| FCF LTM | -107 |
| FCF 3Y Avg | -108 |
| CFO LTM | -106 |
| CFO 3Y Avg | -107 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 56.9% |
| Rev Chg 3Y Avg | 62.1% |
| Rev Chg Q | 45.5% |
| QoQ Delta Rev Chg LTM | 9.6% |
| Op Inc Chg LTM | -17.9% |
| Op Inc Chg 3Y Avg | -36.9% |
| Op Mgn LTM | -23.5% |
| Op Mgn 3Y Avg | -51.8% |
| QoQ Delta Op Mgn LTM | 1.4% |
| CFO/Rev LTM | -9.2% |
| CFO/Rev 3Y Avg | -30.3% |
| FCF/Rev LTM | -9.3% |
| FCF/Rev 3Y Avg | -30.5% |
Price Behavior
null
HELP Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.15 | 1.45 | 1.33 | 2.30 | 0.75 | -1.07 |
| Up Beta | 4.55 | 4.02 | 1.90 | 2.06 | 1.46 | 1.05 |
| Down Beta | -7.74 | -3.09 | 0.23 | 0.79 | -0.82 | -1.02 |
| Up Capture | 699% | 464% | 509% | 563% | 365% | 35% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 14 | 24 | 36 | 63 | 79 | 79 |
| Down Capture | -83% | -153% | -98% | 209% | 151% | 84% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 7 | 18 | 27 | 59 | 80 | 80 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HELP | |
|---|---|---|---|---|
| HELP | 60.6% | 91.3% | 1.20 | - |
| Sector ETF (XLV) | 22.9% | 16.2% | 1.08 | 21.8% |
| Equity (SPY) | 19.4% | 12.8% | 1.11 | 33.4% |
| Gold (GLD) | 20.8% | 29.2% | 0.65 | 21.7% |
| Commodities (DBC) | 45.0% | 20.4% | 1.72 | -16.6% |
| Real Estate (VNQ) | 7.8% | 13.6% | 0.30 | 21.7% |
| Bitcoin (BTCUSD) | -28.1% | 43.9% | -0.63 | 23.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HELP | |
|---|---|---|---|---|
| HELP | 9.9% | 91.3% | 1.20 | - |
| Sector ETF (XLV) | 5.9% | 15.2% | 0.21 | 21.8% |
| Equity (SPY) | 12.6% | 17.2% | 0.56 | 33.4% |
| Gold (GLD) | 18.8% | 18.8% | 0.81 | 21.7% |
| Commodities (DBC) | 10.6% | 19.5% | 0.42 | -16.6% |
| Real Estate (VNQ) | 1.5% | 18.9% | -0.03 | 21.7% |
| Bitcoin (BTCUSD) | 11.1% | 52.6% | 0.39 | 23.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HELP | |
|---|---|---|---|---|
| HELP | 4.8% | 91.3% | 1.20 | - |
| Sector ETF (XLV) | 10.5% | 16.7% | 0.51 | 21.8% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 33.4% |
| Gold (GLD) | 12.2% | 16.3% | 0.61 | 21.7% |
| Commodities (DBC) | 7.9% | 18.1% | 0.36 | -16.6% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 21.7% |
| Bitcoin (BTCUSD) | 63.6% | 66.2% | 1.03 | 23.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 06/29/2026 | 40-F |
| 12/31/2025 | 02/13/2026 | 6-K |
| 09/30/2025 | 11/13/2025 | 6-K |
| 06/30/2025 | 08/14/2025 | 6-K |
| 03/31/2025 | 07/01/2025 | 40-F |
| 12/31/2024 | 02/11/2025 | 6-K |
| 09/30/2024 | 11/13/2024 | 6-K |
| 06/30/2024 | 08/08/2024 | 6-K |
| 03/31/2024 | 06/26/2024 | 40-F |
| 12/31/2023 | 02/14/2024 | 6-K |
| 09/30/2023 | 11/15/2023 | 6-K |
| 06/30/2023 | 08/14/2023 | 6-K |
| 03/31/2023 | 06/27/2023 | 40-F |
| 12/31/2022 | 02/14/2023 | 6-K |
| 09/30/2022 | 11/15/2022 | 6-K |
| 06/30/2022 | 08/08/2022 | 6-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 06/29/2026 | 40-F |
| 12/31/2025 | 02/13/2026 | 6-K |
| 09/30/2025 | 11/13/2025 | 6-K |
| 06/30/2025 | 08/14/2025 | 6-K |
| 03/31/2025 | 07/01/2025 | 40-F |
| 12/31/2024 | 02/11/2025 | 6-K |
| 09/30/2024 | 11/13/2024 | 6-K |
| 06/30/2024 | 08/08/2024 | 6-K |
| 03/31/2024 | 06/26/2024 | 40-F |
| 12/31/2023 | 02/14/2024 | 6-K |
| 09/30/2023 | 11/15/2023 | 6-K |
| 06/30/2023 | 08/14/2023 | 6-K |
| 03/31/2023 | 06/27/2023 | 40-F |
| 12/31/2022 | 02/14/2023 | 6-K |
| 09/30/2022 | 11/15/2022 | 6-K |
| 06/30/2022 | 08/08/2022 | 6-K |
| 03/31/2022 | 06/22/2022 | 40-F |
| 12/31/2021 | 02/10/2022 | 6-K |
| 09/30/2021 | 11/15/2021 | 6-K |
| 06/30/2021 | 08/16/2021 | 6-K |
Investor Activity (13F)
Updated Sep 9, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/8/2026